Cuba on the way to having its own vaccine against the human papillomavirus
The aim is to have a formulated vaccine candidate ready to be evaluated in animal models in 2023.
35 resultados.
The aim is to have a formulated vaccine candidate ready to be evaluated in animal models in 2023.
The vaccine candidate Mambisa - developed by the Center for Genetic Engineering and Biotechnology (CIGB) - is currently in the final stages of clinical trials and, based on the results obtained in the analyses, will apply to the Center for State Control of Medicines, Equipment and Medical Devices for authorization for emergency use as a booster dose in the next few weeks.
The progress of the mass vaccination campaign in the context of COVID-19 in the country has taken place simultaneously with the increase of positive, serious and critical cases and the number of deceased, which have increased the concern among the population about the effectiveness of the vaccines
A Phase I clinical trial based on the treatment of lung injury with autologous stem cells (derived from the patient's own blood) in COVID-19 patients with lung injury demonstrated the safety and efficacy of this therapy in the indication studied
In 2020, tourism in the country declined to a level last seen in 1996, when the landmark first million international visitors arrived, and in 2021 only 356,453 vacationers visited
In just one year of the COVID-19 battle, Cuba has traveled to every continent offering support to 40 countries
Few hours are left for the end of 2022, "a difficult year like few others, and an instructive one like all," as it was recently described by Miguel Díaz-Canel Bermúdez, First Secretary of the Central Committee of the Party and President of the Republic.
Clinical studies showed the Cuban vaccines against COVID-19 have over 90% efficacy.
Faced with the increase of emerging diseases in the world, science advocates paying the same attention to human, animal and plant health.
Mass vaccination in Cuba began precisely at a time when COVID-19 infections were increasing significantly, generating concerns within the population about the effectiveness of our nationally developed vaccines.